533P - Real-world data of treatment and outcome of patients with relapsed ovarian cancer (OC) in Germany (QS ovar of the AGO study group)

Background

Recent and detailed data regarding treatment quality and outcome of patients with relapsed OC on a nationwide basis are largely unknown in Germany.

Methods

All German hospitals treating patients with ovarian cancer were asked to document all patients with first diagnosis in the third quarter in 2012 and in 2016. Details of tumor, treatment and further course of disease were documented. This analysis is focusing on patients with subsequent 1^st relapse of OC, their treatment and outcome. PFS and OS is calculated from start of 2^nd line treatment.

Results

In total, 840 patients with relapsed disease were included, 754 (89.8%) of them had a high-grade histology. The median treatment free interval after end of platinum-based chemotherapy was 12.4 months (range 0-55.7). 144 (17.2%) patients underwent secondary cytoreductive surgery (SCS), complete resection was achieved in 48.6%. 599 received a 2^nd line treatment, which was platinum-based in 445 (74.3%). Out of this cohort, 405 (91.0%) patients had a high-grade histology (387/405 with high-grade serous). 120 patients with high-grade histotype and platinum-based chemotherapy received a PARPi as maintenance therapy. The median PFS and OS of patients receiving a platinum-free versus a platinum-based chemotherapy was 4.6 vs 11.5 months (HR 0.37, 95%-CI 0.30-0.45, p<0.001) and 9.4 vs 20.8 months (HR 0.46, 95%-CI 0.37-0.57, p<0.001), respectively. The rate of progressive disease during platinum-based chemotherapy was 4.7% and 86.1% did not progress within 3 months. Patients with complete resection at SCS had a median PFS and OS of 18.3 and 31.5 months. PFS and OS of patients on PARPi were 15.4 and 33.4 months.

Conclusions

Most patients with 1^st relapse of ovarian cancer were treated with platinum-based chemotherapy with a low number of secondary platinum resistant patients with progressive disease during second-line platinum chemotherapy. SCS and PARPi (which were approved during the follow up-period in Germany) are already part of standard therapy and their outcomes may be superior to platinum-based chemotherapy alone.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

AGO Study Group.

Funding

AstraZeneca, Amgen, Böhringer Ingelheim, Essex, GSK, Roche Pharma AG.

Disclosure

P. Harter: Financial Interests, Personal, Advisory Board, Value includes honoraria for lectures: AstraZeneca; Financial Interests, Personal, Advisory Board, includes honoraria for lectures: GSK, Roche, MSD; Financial Interests, Personal, Invited Speaker: Amgen, Stryker, Zailab; Financial Interests, Personal, Advisory Board: Clovis, ImmunoGen; Financial Interests, Personal, Other, IDMC member: Sotio; Financial Interests, Institutional, Invited Speaker: AstraZeneca, Roche, GSK, Genmab, ImmunoGen; Financial Interests, Institutional, Funding: Seagen, Clovis. A. du Bois: Financial Interests, Personal, Advisory Board: AstraZeneca, Clovis, GSK/Tesaro, Genmab, Amgen; Financial Interests, Personal, Invited Speaker: Zodiac. F. Hilpert: Financial Interests, Personal, Invited Speaker: GSK, AstraZeneca, MSD, PharmaMar; Financial Interests, Personal, Advisory Board: MSD. M. Kerkmann: Financial Interests, Personal, Full or part-time Employment: MMF GmbH; Financial Interests, Institutional, Research Grant: AstraZeneca, Roche, Amgen, Bristol-Myers Squibb, Janssen-Cilag, Pharmacosmos, MSD, Takeda; Non-Financial Interests, Member: Working Group Medical Oncology (AIO) of the German Cancer Society (DKG), Working Group Supportive Care (AGSMO) of the German Cancer Society (DKG), German Cancer Society (DKG). J. Sehouli: Financial Interests, Personal, Advisory Board: Roche, GSK, AstraZeneca, MSD, Tesaro; Financial Interests, Personal, Invited Speaker: Eisei; Financial Interests, Institutional, Funding: Roche, GSK, AstraZeneca; Financial Interests, Institutional, Invited Speaker: Novocure; Non-Financial Interests, Institutional, Proprietary Information: ENGOT/NOGGO; Non-Financial Interests, Leadership Role, Council Member: ESGO. S. Mahner: Financial Interests, Personal, Advisory Board: AbbVie, AstraZeneca, Clovis, Tesaro, MSD; Financial Interests, Personal, Other, Grant: Eisai; Financial Interests, Personal, Invited Speaker: GSK, Pfizer, Roche. N. de Gregorio: Financial Interests, Personal, Advisory Board, Travel expenses: AstraZeneca; Financial Interests, Personal, Advisory Board: Roche, Myriad, GSK, MSD, Clovis, PharmaMar. L. Hanker: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, GSK, MSD, Roche. F. Heitz: Financial Interests, Personal, Invited Speaker: Amedes, Clovis; Financial Interests, Personal, Advisory Board: AstraZeneca, GSK, NovoCure, PharmaMar, Roche; Financial Interests, Institutional, Other, Trial Chair: NewOncology. F. Marmé: Financial Interests, Personal, Invited Speaker: AstraZeneca, GSK/Tesaro, Clovis, Pfizer, Lilly; Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Novartis, Roche, Gilead/Immunomedics, EISAI, PharmaMar, GenomicHealth, Myriad, Seagen; Financial Interests, Institutional, Invited Speaker: Roche, AstraZeneca, Novartis, Roche, Eisai, Gilead/Immunomedics, MSD, German Breast Group, AGO Research GmbH, Vaccibody, GSK; Financial Interests, Institutional, Funding: AstraZeneca. L. Woelber: Financial Interests, Personal, Advisory Board: Sanofi, TESARO/GSK, Roche, MSD, Eisai, Seagen; Financial Interests, Personal, Invited Speaker: Pfizer, Roche, MSD, Medac oncology; Financial Interests, Personal, Other, scientific board: med update GmbH; Financial Interests, Personal, Other, speaker: med publico GmbH; Financial Interests, Institutional, Invited Speaker: Seagene, MSD, Medac Oncology, Vaccibody AS, Roche. L. Holtmann: Financial Interests, Personal, Full or part-time Employment: MMf GmbH; Financial Interests, Institutional, Research Grant: Amgen, AstraZeneca, Bristol Myers-Squibb, Janssen-Cilag, MSD, Pharmacosmos, Roche, Takeda. G. Elser: Other, Employee: AGO Research GmbH. J. Pfisterer: Financial Interests, Personal, Advisory Board: Roche, Amgen, AstraZeneca, Clovis, MSD, GSK, Teva, Lilly; Financial Interests, Institutional, Invited Speaker: Roche, GSK.